Ibogaine and MDMA-assisted therapy both have clinical evidence for PTSD. They work through different mechanisms, suit different patients, and carry different risks. Ibogaine is legal to administer in Canada; MDMA was declined by the FDA in 2024 and remains unavailable outside of clinical trials in North America. They are not interchangeable, and for most people the question is not which is better but which applies to their specific presentation.
Key facts
- Ibogaine (Stanford/Nature Medicine, February 2023): 88% PTSD reduction, 87% depression, 81% anxiety in 30 veterans at 1 month
- MDMA-assisted therapy (MAPS/Nature Medicine, 2021): 67% no longer met PTSD diagnosis vs. 32% placebo
- Ibogaine: legal to administer in Canada; Schedule I in the US
- MDMA: FDA declined approval in 2024; available only through clinical trials in North America
- Ibogaine ceremony duration: 12–24 hours with cardiac monitoring required throughout
- MDMA-assisted therapy: 3 medicine sessions (8 hours each) within an 8–12 week therapy course
- Ibogaine at Transcend: $2,000–$5,000 CAD, including on-site physician and continuous cardiac monitoring
What the Research Actually Shows for Each
The evidence for ibogaine in PTSD comes primarily from the 2023 Stanford study, published in Nature Medicine in February 2023. Thirty special operations veterans with PTSD, traumatic brain injury, and treatment-resistant depression received a single flood dose of ibogaine. At one month post-treatment: PTSD symptoms decreased 88%, depression 87%, anxiety 81%. Conventional antidepressant research considers a 50% reduction in depression scores a “strong response.”
The Stanford study has real limitations worth naming directly. Thirty participants is not a definitive population. There was no placebo arm. The measurement point is one month post-treatment, not six months or two years. The population was specific: special operations veterans with comorbid TBI, PTSD, and treatment resistance. The numbers are compelling enough to stand on their own with those caveats included. Citing them without the caveats is not honest.
The evidence for MDMA-assisted therapy in PTSD is methodologically more developed. The MAPS Phase 3 trial published in Nature Medicine in 2021 was randomised and placebo-controlled: 67% of participants receiving MDMA-assisted therapy no longer met the diagnostic criteria for PTSD at the primary endpoint, compared to 32% of the placebo group. A second Phase 3 trial replicated those findings. Despite this, the FDA declined to approve MDMA-assisted therapy in August 2024, citing concerns about trial methodology—particularly expectancy bias from functional unblinding, the difficulty of running a blind trial when participants can tell whether they received MDMA.
Both research programmes are ongoing and serious. Neither has a decade of randomised controlled trial data. The science is not settled for either approach.
How the Mechanisms Differ
MDMA's mechanism in trauma therapy is primarily neurochemical and relational. It triggers a large release of serotonin, dopamine, and norepinephrine, and significantly elevates oxytocin—producing a state of reduced fear response and increased social openness that allows traumatic material to be processed within a therapeutic relationship. The memory of the trauma is accessed; its emotional charge is reduced; the defensive patterns built around it become less automatic. This happens across three 8-hour medicine sessions embedded within a longer course of psychotherapy.
Ibogaine's mechanism is pharmacologically more complex. It acts simultaneously at opioid receptors (interrupting physical dependence), NMDA receptors (involved in memory consolidation), sigma-2 receptors, and serotonin receptors. It also upregulates glial cell line-derived neurotrophic factor (GDNF)—a protein that promotes the survival and growth of dopaminergic neurons. This GDNF upregulation is part of why ibogaine produces a sustained neuroplasticity window: its primary metabolite, noribogaine, remains biologically active for weeks to months after a single flood dose.
MDMA works with a therapist processing trauma in real time during the session. Ibogaine produces a biographical review—specific memories, recognisable patterns, direct confrontation with material the person has been avoiding—across a 12–24 hour ceremony. These are different processes, suited to different presentations.
Which Patients Each Approach Suits
MDMA-assisted therapy has been researched across a broad PTSD population: combat veterans, survivors of sexual trauma, first responders, civilians. Its cardiac safety profile is less restrictive than ibogaine's—MDMA does not require a pre-session EKG as an absolute requirement.
Ibogaine has the strongest evidence base in three overlapping populations: opioid-dependent individuals seeking to interrupt addiction, veterans with co-occurring PTSD and TBI (the Stanford cohort), and people with treatment-resistant conditions who have not responded to conventional psychiatry.
For someone with PTSD uncomplicated by addiction, no TBI, and normal cardiac function, MDMA-assisted therapy may be the more mechanism-appropriate choice—if legal access allows. For someone with opioid use disorder alongside PTSD, ibogaine is the only compound with a mechanism specific to interrupting physical opioid dependence while simultaneously addressing PTSD. MDMA has no activity at opioid receptors. For this population, the comparison is not between two options for the same condition—it is between two approaches targeting different aspects of a complex presentation.
For the population described in the Stanford data—treatment-resistant, multiple co-occurring diagnoses, history of TBI, years of failed conventional approaches—ibogaine has the most directly relevant clinical evidence. These are people who have already established that other approaches were insufficient.
See ibogaine for TBI for a detailed breakdown of the Stanford study and what the TBI findings specifically mean.
Legal Access and What It Means in Practice
In Canada, ibogaine is not listed under the Controlled Drugs and Substances Act and is not explicitly prohibited. Ceremony at Transcend in Vancouver operates legally. This is a meaningfully different position from the United States, where ibogaine has been Schedule I since 1970.
MDMA remains a Schedule I controlled substance in the United States and a controlled substance in Canada. The FDA's 2024 rejection means MDMA-assisted therapy is not legally available outside of clinical trials in North America. Australia's Therapeutic Goods Administration approved MDMA-assisted therapy for PTSD in February 2023—currently the only jurisdiction with legal access outside of trials.
For someone in Canada seeking legal access to a clinically-supported treatment for PTSD—particularly one with co-occurring opioid dependence, TBI, or treatment resistance—ibogaine ceremony at Transcend in Vancouver is available now. MDMA-assisted therapy requires clinical trial enrollment (limited eligibility, specific criteria) or international travel to Australia.
See what a complete ibogaine therapy programme in Canada includes for a breakdown of what the programme covers and what the costs are.
The Veteran Population and What the Evidence Shows
Special operations veterans are not, as a population, people who enter treatment naively. By the time they arrive at ibogaine ceremony, they have typically been through conventional psychiatric programmes. They have been given diagnoses and medications. Many arrive with a documented history of approaches that did not produce lasting change—and a corresponding scepticism about whether anything will.
The Stanford study documented what practitioners had been observing for years: that ibogaine produces changes in this population that conventional approaches do not. The 88% reduction in PTSD symptoms at one month is striking not only because of the number, but because of who these participants were—people who had already tried everything else and arrived expecting this to fail too. That pattern, prior treatment failure followed by ibogaine-produced reduction in symptom severity, appears consistently across the clinical data.
Texas allocated $50 million USD for clinical ibogaine trials in 2024, distributed across UTMB, UTHealth Houston, Texas A&M, and Baylor University, specifically because of the Stanford data and the treatment gap for this population. The research pipeline is active. See active ibogaine trials on ClinicalTrials.gov for current enrolment status.
Who Is Not a Candidate for Ibogaine
Ibogaine ceremony is not available to everyone with PTSD. The contraindications are not preferences or cautions—they are conditions under which ibogaine cannot be administered safely, and they must be established before any ceremony date is confirmed.
Absolute contraindications:
- QT prolongation or significant cardiac arrhythmia on EKG—ibogaine prolongs the QT interval, and this combination carries a risk of potentially fatal arrhythmia
- Current SSRIs or SNRIs without a completed, physician-supervised taper—serotonin syndrome risk
- Lithium or most antipsychotic medications
- Methadone without a completed transition to a shorter-acting opioid
- Severe liver or kidney disease
- Active psychosis or schizophrenia-spectrum disorder
- Recent myocardial infarction
- Pregnancy
These apply regardless of the severity of the PTSD, the urgency of the situation, or how long someone has been waiting for a treatment that works. There are no exceptions at any legitimate provider. Someone in acute psychiatric crisis is not an appropriate candidate—ibogaine amplifies what is present, and entering it in a state of acute instability does not produce stability.
MDMA-assisted therapy has different contraindications. It does not prolong the QT interval. SSRIs blunt the therapeutic effect of MDMA rather than creating an acute physiological risk. Someone with cardiac contraindications to ibogaine may be a candidate for MDMA-assisted therapy—that assessment belongs with the treating physician, not with this post.
See what cardiac screening for ibogaine involves for a complete discussion of the EKG requirement and what the medical screening process establishes.
Is This Right for You?
If the primary presentation is PTSD with co-occurring opioid dependence, TBI, or documented treatment resistance, ibogaine ceremony has the most directly relevant clinical evidence. The 2023 Stanford data applies to this population.
If the presentation is PTSD without addiction, without cardiac complications, and without treatment resistance, MDMA-assisted therapy—where legally accessible—may be the more appropriate first option. Its evidence base for general PTSD populations is broader. In Canada, access remains restricted to clinical trial enrollment.
If you are considering ibogaine ceremony and the presentation fits, the medical screening is the next step—not a ceremony date. The screening determines whether the contraindications above apply to you. That conversation happens through the application.